Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 3/20 | 0.57 |
| ▸ | THRA | P10827 | 2/20 | 0.57 |
| ▸ | VDR | P11473 | 1/20 | 0.57 |
| ▸ | FASN | P49327 | 16/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13875636 | 0.91 | FASN (0.58) | FASN | |
| SCHEMBL4170959 | 0.84 | FASN (0.55) | FASN | |
| SCHEMBL4175661 | 0.84 | FASN (0.60) | FASN | |
| SCHEMBL4179771 | 0.83 | FASN (0.53) | FASN | |
| SCHEMBL4188743 | 0.82 | FASN (0.64) | FASN | |
| SCHEMBL4183192 | 0.82 | FASN (0.52) | FASN | |
| SCHEMBL4170775 | 0.82 | FASN (0.76) | FASN | |
| SCHEMBL4177029 | 0.81 | FASN (0.52) | FASN | |
| SCHEMBL21451507 | 0.78 | FASN (0.62) | FASN | |
| SCHEMBL4169815 | 0.78 | FASN (0.63) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008075064-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | THRB 3117/4885THRA 3295/4885VDR 2951/4885 |
| US-20090118332-A1 | Therapeutic Agents - 551 | GPR119, FABP4, FASN | THRB 3152/4885THRA 3266/4885VDR 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.